Objective To develop a model for screening for pre-eclampsia (PE) 
INTRODUCTION
In screening for pre-eclampsia (PE) we proposed the use of Bayes theorem to combine the a-priori risk from maternal characteristics and medical history with the results of various combinations of biophysical and biochemical measurements made at different times during pregnancy [1] [2] [3] [4] [5] [6] [7] [8] . We adopted this approach using a competing-risks model for the time to delivery with PE. This model assumes that if the pregnancy was to continue indefinitely, all women would develop PE and whether they do so or not before a specified gestational age depends on competition between delivery before or after development of PE. The effect of maternal factors is to modify the mean of the distribution of gestational age at delivery with PE so that in pregnancies at low risk for PE the gestational age distribution is shifted to the right with the implication that in most pregnancies delivery will actually occur before development of PE. In high-risk pregnancies the distribution is shifted to the left and the smaller the mean gestational age, the higher is the risk for PE. The distribution of biomarkers is specified conditionally on the gestational age at delivery with PE. For any woman with specific maternal factors and biomarker multiples of the median (MoM) values, the posterior distribution of the time to delivery with PE, assuming that there is no other cause of delivery, is obtained from the application of Bayes theorem. Studies in singleton pregnancies have demonstrated that effective screening for PE is achieved by a combination of maternal factors, uterine artery pulsatility index (UtA-PI), mean arterial pressure (MAP) and serum placental growth factor (PlGF) at 11-13 weeks' gestation; serum pregnancy-associated plasma protein-A (PAPP-A) did not provide significant improvement to any combination of biomarkers which included serum PlGF 4, 5 . In twin pregnancy the risk of PE is substantially higher than in singleton pregnancy 9 . In a hypothetical population of singleton pregnancies in which women were of Caucasian racial origin, had weight of 69 kg and height of 164 cm, were nulliparous, had spontaneous conception, no family history of PE and no history of diabetes mellitus, systemic lupus erythematosus or antiphospholipid syndrome, the mean gestational age of delivery with PE was calculated to be 55 weeks 1, 3 . In dichorionic (DC) and monochorionic (MC) twin pregnancies with the same characteristics as singleton pregnancies, the distribution of gestational age at delivery with PE was shifted to the left by 8 and 10 weeks, respectively 10 .
The objective of this study of twin pregnancies with data on MAP, UtA-PI, PlGF and PAPP-A at 11-13 weeks' gestation, was to examine the potential improvement in performance of screening for pre-eclampsia by maternal factors alone with the addition of each biomarker and combinations of biomarkers.
METHODS

Study population
The data for this study were derived from prospective screening for adverse obstetric outcomes in women with twin pregnancy attending their first routine hospital visit at King's College Hospital and Medway Maritime Hospital, UK, between January 2006 and December 2015. This visit, which was held at 11 + 0 to 13 + 6 weeks' gestation, included: first, recording of maternal characteristics and medical history 3, 9 ; second, measurement of MAP by validated automated devices and standardized protocol 11 ; third, measurement of the left and right UtA-PI by transabdominal color Doppler ultrasound and calculation of the mean UtA-PI 12 ; and, fourth, measurement of serum concentration of PlGF and PAPP-A (DELFIA Xpress system; PerkinElmer Life and Analytical Sciences, Waltham, MA, USA). Gestational age was determined by the measurement of fetal crown-rump length 13 of the larger twin. Chorionicity was determined by examining the intertwin membrane at its junction with the placenta 14 . Measurements of biomarkers were carried out for only some of the patients (UtA-PI, n = 1764; MAP, n = 1179; PlGF, n = 1366; PAPP-A, n = 1999: measurements of all four biomarkers were obtained from 1100 pregnancies). The women gave written informed consent to participate in the study, which was approved by the NHS Research Ethics Committee.
The inclusion criteria for this study on screening for PE were twin pregnancy undergoing first-trimester combined screening for aneuploidy and subsequently delivering a phenotypically normal live birth or stillbirth at ≥ 24 weeks' gestation. We excluded pregnancies with aneuploidy or major fetal abnormality, those ending in termination, miscarriage or fetal death before 24 weeks and those with an interval of more than 3 days between the death of one fetus and the live birth of the second twin. For comparison of data from twin pregnancies we obtained results from 35 948 singleton pregnancies, including 1058 (2.9%) that developed PE, with complete data on UtA-PI, MAP, PlGF and PAPP-A that were included in a previous publication 4 .
Outcome measures
Data on pregnancy outcome were collected from the hospital maternity records or the general medical practitioners of the women. The obstetric records of all women with pre-existing or pregnancy-associated hypertension were examined to determine if the condition was PE, as defined by the International Society for the Study of Hypertension in Pregnancy 15 . Outcome measures were delivery with PE at < 32, < 37 and < 42 weeks' gestation.
Statistical analyses
Our model for gestational age at delivery with PE was defined by two components: first, the prior distribution based on maternal factors; and, second, the conditional distribution of biomarker values given the gestational age with PE and maternal factors. We have previously reported the prior distribution for twins by modifying the one for singletons 10 . In this paper we extend the singleton model for the distribution of biomarker values to include twins. Our aim was to do this as simply as possible whilst achieving good screening performance. For the distribution of biomarkers in unaffected twin pregnancies, we assumed the same relationships with gestational age, maternal weight and other factors at the time of measurement as for singleton pregnancies [16] [17] [18] and estimated twin effects that can be applied to produce MoM values for twins. In the case of PAPP-A, MoM values were obtained using our previously published algorithm which provides MoM values for both singleton and twin pregnancies 19 . In twin pregnancies with PE, the distributions of MoM values, conditionally on gestational age at delivery, were compared with those previously reported for singleton pregnancies 4 . The performance of screening for delivery with PE at < 32, < 37 and < 42 weeks' gestation in a mixed population of singleton and twin pregnancies was determined; the number of affected cases was too small to provide separate results for DC and MC twins.
The statistical software package R was used for data analyses 20 . The survival package 21 was used for fitting the maternal factors model, and the package pROC 22 was used for the receiver-operating characteristics (ROC) curve analysis. Data given as median (interquartile range) or n (%). APS, antiphospholipid syndrome; PE, pre-eclampsia; SLE, systemic lupus erythematosus.
RESULTS
Maternal and pregnancy characteristics of the population of 1100 twin and 35 948 singleton pregnancies with available data for all four biomarkers are summarized in Table 1 . Twin pregnancies unaffected by PE, compared with singleton pregnancies, had lower UtA-PI and higher MAP, PlGF and PAPP-A (Table 2, Figure 1 ). In twin pregnancies that developed PE the dependencies of log 10 MoM values of UtA-PI, MAP and PlGF on gestational age at delivery were similar to those previously described for singleton pregnancies ( Figure 2 ) 4 and they all showed significant associations with gestational age at delivery (P < 0.05). In the case of PAPP-A, in twins there was little evidence of any substantive difference between PE and unaffected pregnancies and no evidence of association with gestational age at delivery.
Estimates of standard deviation of log 10 MoM values were similar to those previously described for singletons 4 . The largest discrepancy occurred with PlGF, for which the standard deviation of log 10 MoM was some 25% higher in twins than in singletons; 0.2222 (95% CI, 0.2142-0.2309) in twins compared with 0.1772 (95% CI, 0.1760-0.1785) in singletons 4 . Correlations between log 10 MoM values in twins were consistent with those from singletons. With the exception of PAPP-A, the similarity between the distributional characteristics of marker MoM values in twins and in singletons suggests that the distributional parameters for singleton pregnancies could also be applied in twin pregnancies. We therefore propose, as an initial model for twins, use of the twin-specific prior model 10 with the model for the distributional characteristics for singletons 4 applied to MoM values adjusted by the effects given in Table 2 .
Performance of screening for PE in twins by maternal factors and biomarkers, using this initial model, is shown in the ROC curves in Figure 3 and the areas under the ROC curves in Table 3 . The performance of screening for PE by maternal factors was improved by the addition of each biomarker, and the performance was further improved by the combination of maternal factors, MAP, UtA-PI and PlGF (triple test); addition of PAPP-A did not improve the performance of the triple test. The performance of screening by the triple test using distributional parameters fitted to twins performed slightly better than the initial model (Table 3) . Table 4 provides the screen-positive rate (SPR) and detection rate (DR) in screening of a mixed population of singleton and twin pregnancies at risk cut-offs of 1 in 10, 1 in 50 and 1 in 75 for delivery with PE at < 37 weeks' gestation. At all risk cut-offs the SPR and DR were higher for twin pregnancies than for singleton pregnancies. In combined screening by maternal factors, MAP, UtA-PI and PlGF and risk cut-off of 1 in 75, the DR of PE at < 32, < 37 and < 42 weeks in singleton pregnancies was 91%, 77% and 57%, respectively, at an SPR of 13%; the respective rates for twin pregnancies were 100%, 99% and 97% at an SPR of 75%.
DISCUSSION
Principal findings of this study
In DC twin pregnancies that did not develop PE, compared with singleton pregnancies, UtA-PI was lower, PlGF was higher and MAP was not significantly different.
In MC twins, UtA-PI was lower, MAP was higher and PlGF was not significantly different. In a previous study we found that at 11-13 weeks' gestation the estimated median MoM of PAPP-A was about 2.0 for DC twins and 1.6 for MC twins 19 . In twin pregnancies that developed PE, MAP and UtA-PI at 11-13 weeks' gestation were increased and serum PlGF was decreased. The distribution of biomarkers with gestational age at delivery was similar to the previously reported fitted regression relationships for singleton pregnancies with PE 4 and it was therefore assumed that the same model could be used for both singleton and twin pregnancies. We propose an initial model using a twin-specific prior 10 with biomarker MoM values adjusted for twins, but singleton distributional parameters for biomarkers. The results obtained using this model are marginally worse than those using twin-specific parameters. However, this may be the consequence of the optimistic bias introduced from fitting and testing on the same data.
The performance of screening for PE by maternal factors was improved by the addition of MAP, UtA-PI and PlGF. In screening for PE by the combined test and use of risk cut-off of 1 in 75 to define the high-risk group in a mixed population of singleton and twin pregnancies, the estimated SPR and DR of preterm PE for singletons were 13% and 77%, respectively, and the values for twins were 75% and 99%. Table 4 Screen-positive and detection rates with 95% CI in screening for pre-eclampsia (PE) in singleton and twin pregnancies according to a combination of maternal factors, mean arterial pressure (MAP), uterine artery pulsatility index (UtA-PI) and placental growth factor (PlGF) at risk cut-offs for PE at <37 
Strengths and limitations
The strengths of the study are: first, prospective examination of twin pregnancies attending for routine care in a gestational-age range which is widely used for assessment of gestational age, determination of chorionicity, diagnosis of major fetal defects and screening for trisomies; second, recording of data on maternal characteristics and medical history to identify known risk factors associated with PE and use of a multivariable logistic model to define the prior risk; third, use of a specific methodology and appropriately trained doctors to measure UtA-PI and MAP; fourth, use of automated machines to provide accurate measurement within 40 min of sampling of maternal serum concentration of PlGF and PAPP-A; fifth, expression of the values of the biomarkers as MoMs after adjustment for factors that affect the measurements; and, sixth, use of Bayes theorem to combine the prior risk from maternal factors with biomarkers to estimate patient-specific risks and the performance of screening for PE delivering at different stages of pregnancy. A limitation of the study is that the number of twin pregnancies examined relative to that of singleton pregnancies was inevitably small and we adopted the pragmatic view of using the model that was previously described for singleton pregnancies to examine both singleton and twin pregnancies. This model requires validation and possible adjustments from the study of larger datasets of twins.
Comparison with previous studies
In previous studies we established a competing-risks model for the prediction of PE in singleton pregnancies based on maternal factors and biomarkers 2, 4 . In this study the model has been extended to include twin pregnancies.
Studies on uterine artery Doppler during the second and third trimesters reported that UtA-PI in twin pregnancies is significantly lower than in singleton pregnancies, but the value is increased in pregnancies that develop PE [23] [24] [25] [26] . A study of 421 twin and 500 singleton pregnancies at 11-13 weeks' gestation, in which UtA-PI was measured and values were converted to MoM after correction for maternal body mass index, ethnicity and gestational age, showed that: first, median UtA-PI MoM was similar between MC and DC twins; second, UtA-PI in twins was lower than in singletons; and, third, in twin pregnancies that developed PE at < 34 weeks' gestation, but not in those with PE at ≥ 34 weeks, UtA-PI was increased 27 . Another first-trimester study in 147 twin and 110 singleton pregnancies converted the values to MoM after correction for maternal weight and gestational age; the study reported that: first, UtA-PI in twins was lower than in singletons; second, UtA-PI was higher in MC twins than in DC twins; and, third, in 12 twins that developed PE, median UtA-PI was significantly reduced 28 . This study also measured MAP, converted the values to MoM after correction for maternal weight and gestational age and reported that: first, MAP in twins was not significantly different from that in singletons; second, MAP was unrelated to chorionicity; and, third, in the twin pregnancies that developed PE, median MAP was increased 28 .
A study in 144 twin and 109 singleton pregnancies at 11-13 weeks' gestation measured serum PAPP-A and PlGF, converted the values to MoM and reported that: first, in twin pregnancies PAPP-A and PlGF were approximately twice as high compared with singletons; and, second, in 12 twin pregnancies that developed PE, median PlGF was decreased but PAPP-A was increased 29 . A study in 74 twin and triplet pregnancies and 698 singleton pregnancies measured serum PlGF at 12-18 weeks' gestation and reported that: first, in multiple pregnancies the levels were higher than in singletons; and, second, in five multiple pregnancies that developed PE median PlGF was decreased 30 .
Clinical implications of the study
In singleton pregnancies, effective screening for preterm PE can be provided at 11-13 weeks' gestation by a combination of maternal factors, MAP, UtA-PI and PlGF 4, 5 . Such early identification of high-risk pregnancies is useful because the rate of PE may be reduced by the prophylactic use of low-dose aspirin and/or pravastatin [31] [32] [33] . This study has demonstrated that the same model of screening can be adapted for use in mixed populations of singleton and twin pregnancies.
